Xortx Therapeutics Inc (XRTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -3,313 | -2,158 | -7,719 | -1,318 | -959 |
| Depreciation Amortization | 117 | 140 | 58 | 14 | 15 |
| Accounts receivable | 43 | 21 | -41 | -30 | -32 |
| Other Working Capital | 117 | -1,031 | 1,474 | -1,099 | 270 |
| Other Operating Activity | -643 | -3,555 | -2,736 | -2,405 | 162 |
| Operating Cash Flow | $-3,679 | $-6,583 | $-8,964 | $-4,837 | $-544 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | N/A | -4 | -20 | N/A | N/A |
| Purchase Sale Intangibles | -39 | -42 | -26 | -32 | -11 |
| Other Investing Activity | -39 | -42 | -26 | -32 | -11 |
| Investing Cash Flow | $-39 | $-46 | $-46 | $-32 | $-11 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 3,517 | 0 | 5,000 | 20,197 | 672 |
| Other Financing Activity | -738 | -361 | -290 | -683 | -33 |
| Financing Cash Flow | $2,780 | $-361 | $4,710 | $19,514 | $639 |
| Exchange Rate Effect | -36 | 4 | -136 | 260 | N/A |
| Beginning Cash Position | 3,448 | 10,434 | 14,870 | 137 | 44 |
| End Cash Position | 2,474 | 3,448 | 10,434 | 15,041 | 128 |
| Net Cash Flow | $-974 | $-6,987 | $-4,436 | $14,905 | $84 |
| Free Cash Flow | |||||
| Operating Cash Flow | -3,679 | -6,583 | -8,964 | -4,837 | -544 |
| Capital Expenditure | N/A | -4 | -20 | N/A | N/A |
| Free Cash Flow | -3,679 | -6,588 | -8,983 | -4,837 | -544 |